UNCOMPROMISING COMMITMENT TO PATIENTS
David and Goliath Pharma is a privately owned company licensed to operate across the value chain of medical cannabis, from strain enhancement, to cultivation, production, and distribution. Our uncompromising commitment to patients is at the core of what we do, ensuring they get a high quality and continuous supply of medical cannabis. Our teams have years of extensive experience in the pharmaceutical and medical cannabis industry.
PRODUCTS
SERVICES
BREEDING
Since we want to oversee and control the entire process of growing, producing, and distributing medical-grade cannabis products, we carry out the entire cannabis breeding process. We implement a variety of techniques and work according to strict protocols in order to grow high-quality strains, especially with identical components, in all growth cycles.
GROWTH
The goal of all growth processes is to deliver a product that is grown, processed, and shipped while preserving its original qualities.
PRODUCTION
We’ve set up a state-of-the-art facility in the industrial area of the Be’er Tuvia Regional Council in southern Israel. Our facility is in strict compliance with the Israeli IMC-GMP standard and the EU-GMP European standard. We employ innovative technology to extract cannabis inflorescence for medical use, which enables the production of advanced cannabis products composed of the precise ratio of active ingredients. All processes and machinery in the facility are designed, produced, and operated in order to properly maintain the quantity and quality of the active ingredients in the cannabis plant.
RESEARCH
We are committed to ongoing research in order to improve the quality of care and assist patients through the use of medical-grade cannabis.
David and Goliath partner in cutting-edge research, some already in its advanced stages, in order to improve the quality of medical cannabis treatment, as well as to tailor treatment to each patient according to their specific needs. Our main focus is to overcome one of the greatest barriers for medical cannabis, which is routes of administration and their efficacy. Our R&D department, in collaboration with third party experts, are working on additional routes of administration.
